Presentation to Highlight COPD Exacerbation Rates Observed in Phase 3 Program of YUPELRI in Patients with Moderate to Very Severe COPD DUBLIN and HERTFORDSHIRE, England and PITTSBURGH , Sept. 11, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma ") and Mylan
We are pleased to confirm that on Aug. 31, 2018, Mylan closed an agreement with Novartis to purchase the worldwide rights to commercialize their global cystic fibrosis products consisting of TOBI Podhaler® and TOBI® solution, which will further enhance Mylan’s respiratory portfolio in the U.S.,
- Tadalafil is indicated in the treatment of pulmonary arterial hypertension to improve exercise ability - - Mylan awarded 180 days of marketing exclusivity - HERTFORDSHIRE, England and PITTSBURGH , Aug. 13, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V.
HERTFORDSHIRE, England , Aug. 8, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V.'s (NASDAQ: MYL) board of directors today released the following statement: Over the past decade, Mylan's Board of Directors and management team have turned Mylan into a leading global platform with a
HERTFORDSHIRE, England and PITTSBURGH , Aug. 8, 2018 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced its financial results for the quarter and six months ended June 30, 2018. Second Quarter 2018 Financial Highlights Total revenues of $2.81 billion , down 5% compared to the prior year
HERTFORDSHIRE, England , and PITTSBURGH , July 31, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will release its second quarter 2018 financial results, on Wed., Aug. 8 , before the open of the U.S.
HERTFORDSHIRE , England and PITTSBURGH, and TOKYO , July 27, 2018 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Fujifilm Kyowa Kirin Biologics Co., Ltd. today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the
U.S. Court of Appeals for the Federal Circuit rejects Allergan's attempt to use tribal sovereign immunity to avoid Restasis® patent challenge Mylan's IPR challenges to Restasis® patents can proceed Federal District Court previously held patents invalid HERTFORDSHIRE, England and PITTSBURGH, July
- The launch of Rivastigmine Transdermal System highlights Mylan's continued investment in difficult-to-manufacture products - HERTFORDSHIRE, England and PITTSBURGH , July 9, 2018 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Rivastigmine Transdermal System, 4.6 mg/24
Mylan is committed to maintaining the highest quality manufacturing standards at its facilities around the world. In support of this commitment, Mylan’s plants are regularly inspected by health authorities to ensure compliance for the various markets we serve. The U.S.